Arcus Biosciences Quote, Financials, Valuation and Earnings

Arcus Biosciences Price Quote

-0.04 (-3.26%)
(Updated: February 4, 2023 at 4:28 AM ET)

Arcus Biosciences Key Stats

Arcus Biosciences (RCUS) is a Sell

Day range:
$20.32 - $21.05
52-week range:
$16.74 - $39.75
Dividend yield:
P/E ratio:
P/S ratio:
P/B ratio:

Avg. volume:
1-year change:
Market cap:

How Much Does Arcus Biosciences Make?

Is Arcus Biosciences Growing As A Company?

  • What Is Arcus Biosciences's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 2.55%
  • What Is Arcus Biosciences's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Arcus Biosciences Stock Price Performance

What Is Arcus Biosciences 52-Week High & Low?

Arcus Biosciences Price To Free Cash Flow

Is It Risky To Buy Arcus Biosciences?

  • How Much Debt Does Arcus Biosciences Have?
    Total long term debt quarterly is $0
  • How Much Cash Does Arcus Biosciences Have?
    Cash and short term investments quarterly total is $1B
  • What Is Arcus Biosciences’s Book Value Per Share?
    Book value per share is 9.68

Is Arcus Biosciences Cash Flow Positive?

  • What Is RCUS Cash Flow From Operations?
    Cash flow from operations (TTM) is $445.6M
  • What Is Arcus Biosciences’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $33.5M
  • What Is Arcus Biosciences’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$440.9M

Arcus Biosciences Return On Invested Capital

  • Is Management Doing A Good Job?
    RCUS return on invested capital is 11.01%
  • What Is Arcus Biosciences Return On Assets?
    ROA measures how assets are converting to revenues and is 5.83%
  • What Is RCUS Return On Equity?
    ROE is a measure of profitability and is 11.01%

Arcus Biosciences Earnings Date & Stock Price

Arcus Biosciences Competitors

  • Who Are Arcus Biosciences's Competitors?
    Below is a list of companies who compete with Arcus Biosciences or are related in some way:
    • Cytokinetics Inc (CYTK)
    • Gilead Sciences Inc (GILD)
    • Madrigal Pharmaceuticals Inc (MDGL)
    • Entrada Therapeutics Inc (TRDA)
    • Vertex Pharmaceuticals Inc (VRTX)

Arcus Biosciences Dividend Yield

Data Unavailable

Arcus Biosciences Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 9.86%
Revenue: 254.94% 51.56%

Analyst Recommendations

Buy Recommendations: 8
Hold Recommendations: 2
Sell Recommendations: 0
Price Target: 42.82
Upside from Last Price: 108.77%

Major Shareholders

  • How many RCUS shares are owned by institutional investors?
    83M RCUS shares are owned by institutional investors
  • How many RCUS shares are owned by insiders?
    1.7M RCUS shares are owned by insiders